Previous 10 | Next 10 |
Nyxoah Announces CE Mark Approval for Genio® 2.1 The next generation external activation chip leverages Nyxoah’s scalable platform to continuously enhance patient comfort and therapy efficacy Mont-Saint-Guibert, Belgium – July 18, 2022, 10:30pm CET...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re diving into all of the latest stock news on Monday with our breakdown of the biggest pre-market stock movers for today! Moving stocks this morning is FDA news, stock ac...
The shares of Nyxoah S.A., surged ~31% in the pre-market Monday after the Belgium-based medTech company announced that the FDA greenlighted a clinical trial to study its neurostimulation therapy Genio system for a type of sleeping disorder. The FDA issued Investigational Devic...
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Receives FDA IDE Approval to Initiate the ACCCESS Study of Genio® in Complete Concentric Collapse Patients First ACCCESS patient expected to be implanted in Q4 2022 Mont-Saint-Guibert, Belgium – July...
Gainers: Cowen ( COWN ) +16% . CommScope Holding Company ( COMM ) +5% . Red Robin Gourmet Burgers ( RRGB ) +3% . The RealReal ( REAL ) +2% . AbCellera Biologics ( ABCL ) +2% . Losers: Nyxoah ( NYXH ) -7% . Ovi...
Nyxoah Joins the Euronext Tech Leaders Initiative, Included in the Euronext Tech Leaders Index Mont-Saint-Guibert, Belgium – June 7, 2022 4:30pm ET / 10:30pm CET– Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a ...
FDA Approves Genio® 2.1 For Use in DREAM U.S. IDE Pivotal Study New smartphone application, upgraded activation chip, improved user interface, and stimulation amplitude trimming enhance patient experience and comfort Mont-Saint-Guibert, Belgium – June 1, ...
Image source: The Motley Fool. Nyxoah S.A. (NASDAQ: NYXH) Q1 2022 Earnings Call May 10, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Nyxoah S.A. (NYXH) Q1 2022 Earnings Call Transcript
Nyxoah press release (NASDAQ:NYXH): Q1 GAAP EPS of -€0.26. Revenue of €0.66M (+247.4% Y/Y). For further details see: Nyxoah GAAP EPS of -€0.26, revenue of €0.66M
REGULATED INFORMATION Nyxoah Reports First Quarter 2022 Financial and Operating Results Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), ...
News, Short Squeeze, Breakout and More Instantly...
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the ...
REGULATED INFORMATION INSIDE INFORMATION Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank Mont-Saint-Guibert, Belgium – July 3, 2024, 12:30pm CET / 6:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (&...
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the develop...